The DOI matches its Crossref record; 140 of the 141 references it cites were found in a registry or an index.
Comparative Risk for Harms of Second-Generation Antidepressants: A Systematic Review and Meta-Analysis
Abstract
Background Evidence indicates that only minor differences in efficacy exist among second-generation antidepressants for the treatment of major depressive disorder (MDD). However, a comprehensive assessment of both benefits and harms is crucial to evaluate the net benefit.Objective To review systematically the comparative harms of second-generation antidepressants for the treatment of MDD in adults by including both experimental and observational evidence.Data sources We searched MEDLINE, EMBASE, PsychLit, The Cochrane Library and the International Pharmaceutical Abstracts from 1980 to April 2007. We manually searched reference lists of pertinent review articles and explored the Center for Drug Evaluation and Research database to identify unpublished research.Study selection Eligible study designs were trials and observational studies comparing one drug of interest with another.Data extraction Two persons independently reviewed abstracts and full-text articles. One investigator extracted relevant data. A senior reviewer checked data for completeness and accuracy.Data synthesis We included 104 experimental and observational studies. If data were sufficient, we conducted meta-analyses of randomized controlled trials on the relative risk of specific adverse events. Findings indicate that the spectrum of adverse events is similar. The frequency of specific adverse events, however, differed across drugs. Venlafaxine was associated with a significantly higher rate of nausea and vomiting than selective serotonin reuptake inhibitors. Compared with other drugs, paroxetine frequently led to more sexual adverse effects and bupropion to fewer such effects; mirtazapine and paroxetine was associated with more weight gain and sertraline with a higher rate of diarrhoea. Overall, however, these differences did not lead to different discontinuation rates. The evidence is insufficient to draw conclusions about rare but severe adverse events.Conclusions Adverse event profiles are similar among second-generation antidepressants. However, different frequencies of specific adverse events might be clinically relevant and influence the choice of a treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“around 60% of patients using second-generation antidepressants, such as selective serotonin reuptake inhibitors [SSRIs] encountered adverse events, and 7% to 15% quit treatment due to the events (Gartlehner et al. 2008)”
From A Scoping Review of Correctional-Based Interventions for Women Prisoners with Mental Health Problems (2023) · cites this paper as Gartlehner et al. 2008
In the citing paper
“A meta-analysis further showed that the relative risk of nausea and vomiting for venlafaxine was higher than those for SSRIs with RR of 1.53 (95% CI, 1.26–1.86).44”
From Addressing the Side Effects of Contemporary Antidepressant Drugs: A Comprehensive Review (2018) · cites this paper as [44]
Citations
Cites
Goodman & Gilman's The Pharmacological Basis of Therapeutics
Brunton, L. L. (1985) · Cited by 7,321
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Stigelman, W. H., & Pharm, D. (1986) · Military Medicine · doi:10.1093/milmed/151.1.386 · Cited by 6,796
Evaluating non-randomised intervention studies
Deeks, J., Dinnes, J., D'Amico, R., Sowden, A., Sakarovitch, C., Song, F., Petticrew, M., & Altman, D. (2003) · Health Technology Assessment · doi:10.3310/hta7270 · Cited by 2,907
Current methods of the U.S. Preventive Services Task Force
Harris, R., Helfand, M., Woolf, S. H., Lohr, K. N., Mulrow, C. D., Teutsch, S. M., & Atkins, D. C. (2001) · American Journal of Preventive Medicine · doi:10.1016/s0749-3797(01)00261-6 · Cited by 1,720
Self-citationSystematic Reviews in Health Care: Meta‐Analysis in Context
(2001) · doi:10.1002/9780470693926 · Cited by 1,693
Better Reporting of Harms in Randomized Trials: An Extension of the CONSORT Statement
Ioannidis, J. P. A., Evans, S. J. W., Gøtzsche, P. C., O'Neill, R. T., Altman, D. G., Schulz, K., Moher, D., & for the CONSORT Group* (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-10-200411160-00009 · Cited by 1,593
Network meta‐analysis for indirect treatment comparisons
Lumley, T. (2002) · Statistics in Medicine · doi:10.1002/sim.1201 · Cited by 1,206
Antidepressants and the Risk of Suicidal Behaviors
Jick, H. (2004) · JAMA · doi:10.1001/jama.292.3.338 · Cited by 587
Prevalence of Sexual Dysfunction Among Newer Antidepressants
Clayton, A. H., Pradko, J. F., Croft, H. A., Montano, C. B., Leadbetter, R. A., Bolden-Watson, C., Bass, K. I., Donahue, R. M. J., Jamerson, B. D., & Metz, A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0414 · Cited by 542
Montejo, A. L., Llorca, G., Izquierdo, J. A., & Rico‐Villademoros, F. (2001) · PubMed · Cited by 460
Research works printed but not linked: 16
- Gartlehner, 2006, J Clin Epidemiol, 60, 753
- Feighner, 1991, J Clin Psychiatry, 52, 329
- Tylee, 1997, Primary Care Psychiatry, 3, 51
- Alves, 1999, Primary Care Psychiatry, 5, 57
- Bennie, 1995, J Clin Psychiatry, 56, 229
- Beasley Jr, 1991, J Clin Psychiatry, 52, 294
- Cunningham, 1994, JClin Psychopharmacol, 14, 99
- Perry, 1989, J Clin Psychiatry, 50, 290
- Lepola, 2003, Int Clin Psychopharmacol, 18, 211, 10.1097/00004850-200307000-00003 · DOI · Paper page
- Patris, 1996, Int Clin Psychopharmacol, 11, 129
- Kasper, 2005, Am J Geriatr Psychiatry, 13, 884, 10.1097/00019442-200510000-00008 · DOI
- Gagiano, 1993, Br J Clin Res, 4, 145
- Johnston, 1991, J Clin Psychiatry, 52, 450
- Mackay, 1999, Br J Gen Pract, 49, 892
- Mackay, 1999, Br J Gen Pract, 49, 871
- Liu, 1996, CMAJ, 155, 519
Cited by
Sorted by citations
A Meta-Analysis of Cytokines in Major Depression
Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E. K., & Lanctôt, K. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.033 · Cited by 4,729
Malhi, G. S., Bassett, D., Boyce, P., Bryant, R., Fitzgerald, P. B., Fritz, K., Hopwood, M., Lyndon, B., Mulder, R., Murray, G., et al. (2015) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867415617657 · Cited by 842
“It is important to note that there is considerable variability among antidepressants in the nature and severity of side-effects, and these also vary from one individual to another (Gartlehner et al., 2008, 2011).”
BackgroundDepression and anxiety in inflammatory bowel disease: A review of comorbidity and management
Graff, L. A., Walker, J. R., & Bernstein, C. N. (2009) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20873 · Cited by 586
Kennedy, S. H., Lam, R. W. M., Parikh, S. V., Patten, S. B., & Ravindran, A. V. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.043 · Cited by 529
Lam, R. W., Kennedy, S. H., Grigoriadis, S., McIntyre, R. S., Milev, R., Ramasubbu, R., Parikh, S. V., Patten, S. B., & Ravindran, A. V. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.041 · Cited by 431
Metadata
- Authors
- Gartlehner, G., Thieda, P., Hansen, R. A., Gaynes, B. N., DeVeaugh-Geiss, A., Krebs, E. E., & Lohr, K. N.
- Affiliations
- Universität für Weiterbildung Krems (AT)
- University of North Carolina at Chapel Hill (US)
- Regenstrief Institute (US)
- RTI International (US)
- Corresponding author
- Gartlehner, Gerald
- Venue
- Drug Safety
- Published
- 2008
- Volume
- 31
- Issue
- 10
- Pages
- 851-865
- ISSN
- 0114-5916 (ISSN-L)
- OpenAlex
- W2006078781
- Cited by
- 150
- References
- 141
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 4 · 2023: 8 · 2022: 7 · 2021: 8 · 2020: 4 · 2019: 7 · 2018: 3 · 2017: 6 · 2016: 9 · 2015: 10 · 2014: 7 · 2013: 11 · 2012: 10
- FWCI
- 9.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Drug Safety (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Public Health Service (290-02-0016)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- second-generation antidepressants, major depressive disorder, adverse drug reactions, drug safety comparison, venlafaxine, selective serotonin reuptake inhibitors, paroxetine, bupropion, mirtazapine, sertraline, sexual adverse effects, weight gain, nausea and vomiting, diarrhea, discontinuation rate, net benefit
- MeSH terms
- Adult, Blood Pressure, Depressive Disorder, Major, Major Depressive Disorder, Humans, Nausea, Seizures, Sexual Dysfunction, Physiological, Vomiting, Treatment Outcome, Risk Assessment, Antidepressive Agents, Second-Generation, Sexual Dysfunctions, Psychological
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
